Floatz logo

Retinol

Tuberculosis

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Tuberculosis cohort.

View all 10

Same molecule, other indications

Retinol is also rated in:

relapsing-remitting multiple sclerosisDormant
BB
Indicative · Phase 4
65 / 100
View asset →
vitamin A deficiencyActive
B
Indicative · Phase 2
57 / 100
View asset →
HIV infectious diseaseDormant
B
Indicative · Phase 2
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →